Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes
In this comparative effectiveness study in veterans with diabetes, liraglutide, semaglutide, and dulaglutide initiators had similar risks for kidney and cardiovascular outcomes. Head-to-head randomized trials are needed to confirm these findings.
Authors
- Vikrant Deshmukh (ORCID: https://orcid.org/0000-0001-6670-8245)
- Jincheng Shen (ORCID: https://orcid.org/0000-0002-6551-3558)
- Tom Greene (ORCID: https://orcid.org/0000-0002-3706-7570)
- Catherine G. Derington (ORCID: https://orcid.org/0000-0001-7382-4607)
- Stavros G. Drakos (ORCID: https://orcid.org/0000-0002-1223-327X)
- Sydney E. Hartsell (ORCID: https://orcid.org/0000-0001-7328-3732)
- Robert E. Boucher (ORCID: https://orcid.org/0000-0002-5455-002X)
- Srinivasan Beddhu (ORCID: https://orcid.org/0000-0002-3312-315X)
- Ravinder Singh (ORCID: https://orcid.org/0000-0002-7221-8557)
- Amara Sarwal
- P Veeresh Babu
- McKenna Nevers
- Chong Zhang (ORCID: https://orcid.org/0000-0002-5014-4331)
- Niharika Katkam
- Guo Wei (ORCID: https://orcid.org/0000-0002-4971-8430)
- Augustine Takyi
- Akhil Ramanujam Chakravartula
- Michael J Throolin
Institutions
- Outcomes Research Consortium (US)
- University of Utah (US)
- VA Salt Lake City Healthcare System (US)
- Echelon Biosciences (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.37297
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47